PDX Live™: Efficacy Studies on Demand

Type:

Additional live models may be available, and are subject to change.

For specific model availability, please contact:

Technical Information Services
micetech@jax.org
1-800-422-6423 (US, Canada & Puerto Rico)
1-207-288-5845 (from any location)
JAX Technical Support

Study types 1-3 include the following:

• 8 mice per arm (NSG™)
• IV or IP dosing – (Oral dosing includes an additional charge)
• Maximum of 28 day study duration
• Twice weekly tumor caliper measurements and body weight
• Simple necropsy with tumor collection and up to 3 tissues (or blood)
• Analytical Study Report

Tolerability studies include the following:

• 5 mice per arm
• IV or IP dosing – no limit on frequency (Oral dosing includes an additional charge)
• Cage observation – 14 days
• Study report

We provide you data in weeks with study-ready clinically relevant patient-derived xenografts in the most robust mouse models.

Questions?

Contact Technical Support
micetech@jax.org
1.800.422.6423 (US)
1.207.288.5845 (International)

Pilot Combination Study Using a PDX Live™ Colon Adenocarcinoma

Figure 1. Mice bearing passage 3 colon adenocarcinoma PDX tumor (TM00170) were treated with vehicle control: D5W (dark grey), 20mg/ kg 5-Fu (light blue), 10mg/kg Oxaliplatin (orange) and 5-Fu + Oxaliplatin (dark blue) once per week for 3 weeks. Vehicle and 5-Fu were administrated intravenously and Oxaliplatin was dosed intraperitoneally. The readout for compound efficacy–alone or in combination-was assessed by taking tumor caliper measurements and body weight twice weekly. Ten NSG™ mice were used per arm.

Pilot Combination Study Using a PDX Live™ Invasive Ductal Carcinoma

Figure 2. Mice bearing passage 4 TM00089 PDX tumor were treated with vehicle control (D5W), Cisplatin (2mg/kg), Cyclophosphamide (40mg/kg) and Doxorubicin (2mg/kg) intravenously, once per week for 3 weeks; Docetaxel (15mg/kg) was dosed once per week only for 2 weeks intravenously.

3A.

3B.

3C.

Figure 3. A) Patient tumor for PDX model TM00089 (aka, BR0620); PR marker (negative). B) P0 tumor #037 for PDX model TM00089 (aka, BR0620F); estradiol supplemented; PR marker. C) P1 tumor for PDX model TM00089 (aka, BR0620F); estradiol supplemented; PR marker (negative)

Pilot Combination Study Using a PDX Live™ Lung Adenocarcinoma

Figure 4. Mice bearing TM00199 PDX samples at passage 3 were used to create five treatment groups of twelve mice each: vehicle control (0.5 % carboxymethylcellulose); erlotinib (50 mg/kg); afatinib (20 mg/kg); cetuximab (10 mg/kg); and afatinib plus cetuximab (20 mg/kg and 10 mg/kg, respectively). Vehicle, erlotinib, and afatinib were IP dosed daily for 21 days. Cetuximab was dosed intravenously three times weekly, for three weeks. Mice were monitored for tumor volume.

5A.

5B.

Figure 5. A) P1 tumor #940_001 for PDX model TM00199 (aka, LG0703F). B) P1 tumor #940_006 for PDX model TM00199 (aka, LG0703F).